Biocon looking for partners to develop and market psoriasis drug

06 Jun 2013 Evaluate

Biocon, Asia's premier biotechnology company, is looking for partner to develop and market its novel biologic drug Itolizumab, branded as ‘Alzumab’. In January 2013, the company had received marketing authorization for Itolizumab from the Drugs Controller General of India (DCGI). The company as such has not identified any potential partners and about the financial contours of the partnership for Itolizumab. It is currently preparing launch of the product in India. This is the company’s second novel biologic developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first.

Itolizumab is used for the treatment of chronic plaque psoriasis worldwide. Psoriasis is an inflammatory auto-immune skin disease that follows a typical relapsing and remitting course with the disease affecting 2-3% of the world’s population. The global market for the psoriasis treatments is expected to reach $8 billion by 2016.

Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

390.25 -5.00 (-1.27%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×